← Leaderboards
Bruce M Psaty
University Of Washington
$64,428,295
Attributed
$86,862,926
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$96,225,842 · 21
By mechanism
R01$69,794,968 · 16
U01$26,171,248 · 4
T32$259,626 · 1
Top collaborators
- Russell P Tracy16 shared
- Kenneth M. Rice9 shared
- Stephen S. Rich9 shared
- Gregory L Burke5 shared
- Richard A Kronmal5 shared
- Robert E Gerszten4 shared
- George Howard4 shared
- Steven J Kittner4 shared
Most similar at University Of Washington
Same institution · by research overlap
- Michael G McDonell$9,663,091
- Jashvant D Unadkat$14,909,800
- Andre Michael Lieber$20,253,196
- Sridhar Mani$6,137,733
- Evan D Kharasch$17,406,013
Others in their field
Top investigators on “Cardiovascular System”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Judith S. Currier · University Of California Los Angeles$139,907,800
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$137,892,773
- Judith S Hochman · New York University School Of Medicine$110,228,771
Research focus
Cardiovascular SystemResearch PersonnelCohort StudiesParticipantEventRisk FactorsCohortAgingFundingStrokeGeneticVariantGenetic VariantPhenotypeFutureGenotypeGenome Wide Association StudyEpidemiologyWorking GroupAtrial FibrillationHeartDiabetes MellitusCollaborationsCardiovascular Health
Grant awards (92)
Infrastructure for mentored access to CHS data and specimens$1,372,795
R01 · FY2025 · HL · contact PI
CHARGE consortium: omics discovery for CVD and aging phenotypes$580,749
R01 · FY2024 · HL · contact PI
CHARGE consortium: omics discovery for CVD and aging phenotypes$604,112
R01 · FY2023 · HL · contact PI
Plasma proteomics in CHS and population biology$1,073,392
R01 · FY2022 · HL · contact PI
CHARGE consortium: omics discovery for CVD and aging phenotypes$647,561
R01 · FY2022 · HL · contact PI
Plasma proteomics in CHS and population biology$1,076,097
R01 · FY2021 · HL · contact PI
Innate and adaptive immune-cell densities as risk factors for heart failure$677,311
R01 · FY2021 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$675,343
R01 · FY2021 · HL · contact PI
Plasma proteomics in CHS and population biology$2,083,439
R01 · FY2020 · HL · contact PI
Innate and adaptive immune-cell densities as risk factors for heart failure$685,835
R01 · FY2020 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$676,646
R01 · FY2020 · HL · contact PI
Plasma proteomics in CHS and population biology$1,799,932
R01 · FY2019 · HL · contact PI
CHS research resources for the cardiovascular health of older adults$1,552,443
U01 · FY2019 · HL · contact PI
Innate and adaptive immune-cell densities as risk factors for heart failure$736,213
R01 · FY2019 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$687,788
R01 · FY2019 · HL · contact PI
CHS research resources for the cardiovascular health of older adults$1,538,449
U01 · FY2018 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$985,696
U01 · FY2018 · HL · contact PI
Innate and adaptive immune-cell densities as risk factors for heart failure$741,580
R01 · FY2018 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$734,456
R01 · FY2018 · HL · contact PI
CHS research resources for the cardiovascular health of older adults$397,655
U01 · FY2018 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$3,896,325
U01 · FY2017 · HL · contact PI
CHS research resources for the cardiovascular health of older adults$1,556,769
U01 · FY2017 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$691,102
U01 · FY2017 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$668,616
R01 · FY2017 · HL · contact PI
T-cell subsets as CVD risk factors in CHS and MESA$550,131
R01 · FY2017 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$3,000,000
R01 · FY2016 · HL · contact PI
CHS research resources for the cardiovascular health of older adults$1,577,728
U01 · FY2016 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$690,532
R01 · FY2016 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$668,583
R01 · FY2016 · HL · contact PI
T-cell subsets as CVD risk factors in CHS and MESA$635,172
R01 · FY2016 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$2,394,488
R01 · FY2015 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$719,875
R01 · FY2015 · HL · contact PI
T-cell subsets as CVD risk factors in CHS and MESA$707,950
R01 · FY2015 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$685,818
R01 · FY2015 · HL · contact PI
Genomics and pharmacodynamics of statin-related rhabdomyolysis$614,753
R01 · FY2015 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$1,416,026
R01 · FY2014 · HL · contact PI
Prospective meta-analyses of drug-gene interactions: CHARGE GWAS consortium$1,344,491
R01 · FY2014 · HL · contact PI
CHS Events Follow-up Study$1,259,929
R01 · FY2014 · HL · contact PI
Rare variants and NHLBI traits in deeply phenotyped cohorts$762,806
R01 · FY2014 · HL · contact PI
T-cell subsets as CVD risk factors in CHS and MESA$726,570
R01 · FY2014 · HL · contact PI
Genomics and pharmacodynamics of statin-related rhabdomyolysis$634,759
R01 · FY2014 · HL · contact PI
Prospective meta-analyses of drug-gene interactions: CHARGE GWAS consortium$1,290,419
R01 · FY2013 · HL · contact PI
CHS Events Follow-up Study$1,223,976
R01 · FY2013 · HL · contact PI
The NINDS International Stroke Genetics Consortium Study$1,202,540
U01 · FY2013 · NS
CHARGE consortium: gene discovery for CVD and aging phenotypes$636,606
R01 · FY2013 · HL · contact PI
Genomics and pharmacodynamics of statin-related rhabdomyolysis$615,504
R01 · FY2013 · HL · contact PI
The NINDS International Stroke Genetics Consortium Study$1,440,297
U01 · FY2012 · NS
Prospective meta-analyses of drug-gene interactions: CHARGE GWAS consortium$1,341,853
R01 · FY2012 · HL · contact PI
CHS Events Follow-up Study$1,268,677
R01 · FY2012 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$668,917
R01 · FY2012 · HL · contact PI
Genomics and pharmacodynamics of statin-related rhabdomyolysis$546,350
R01 · FY2012 · HL · contact PI
CVD Epidemiology Training Program$259,626
T32 · FY2012 · HL · contact PI
The NINDS International Stroke Genetics Consortium Study$3,029,472
U01 · FY2011 · NS
Prospective meta-analyses of drug-gene interactions: CHARGE GWAS consortium$1,398,235
R01 · FY2011 · HL · contact PI
CHARGE consortium: gene discovery for CVD and aging phenotypes$714,770
R01 · FY2011 · HL · contact PI
The NINDS International Stroke Genetics Consortium Study$3,690,607
U01 · FY2010 · NS
Genome-wide case-only study of antihypertensive drug-gene interactions$1,708,531
R01 · FY2010 · HL · contact PI
CHS Events Follow-up Study$1,247,777
R01 · FY2010 · HL · contact PI
Genome-wide case-only study of antihypertensive drug-gene interactions$1,676,225
R01 · FY2009 · HL · contact PI
CHS Events Follow-up Study$1,295,541
R01 · FY2009 · HL · contact PI
WGA Study to Identify Genetic Variants Associated with CV Events in CHS$1,183,527
R01 · FY2009 · HL · contact PI
Genome-wide case-only study of antihypertensive drug-gene interactions$1,828,582
R01 · FY2008 · HL · contact PI
WGA Study to Identify Genetic Variants Associated with CV Events in CHS$1,381,866
R01 · FY2008 · HL · contact PI
CHS Events Follow-up Study$1,353,530
U01 · FY2008 · HL · contact PI
Pharmacoepidemiology and Pharmacogenetics of a Statin AE$428,229
R01 · FY2008 · HL · contact PI
WGA Study to Identify Genetic Variants Associated with CV Events in CHS$2,502,645
R01 · FY2007 · HL · contact PI
Genome-wide case-only study of antihypertensive drug-gene interactions$1,946,907
R01 · FY2007 · HL · contact PI
CHS Events Follow-up Study$1,145,576
U01 · FY2007 · HL · contact PI
Pharmacoepidemiology and Pharmacogenetics of a Statin AE$501,301
R01 · FY2007 · HL · contact PI
CHS Events Follow-up Study$1,055,034
U01 · FY2006 · HL · contact PI
Pharmacogenetics and Cardiovascular Events$670,616
R01 · FY2006 · HL · contact PI
Pharmacoepidemiology and Pharmacogenetics of a Statin AE$570,316
R01 · FY2006 · HL · contact PI
CHS Events Follow-up Study$1,058,025
U01 · FY2005 · HL
Pharmacogenetics and Cardiovascular Events$700,395
R01 · FY2005 · HL
Pharmacoepidemiology and Pharmacogenetics of Statin AE$599,165
R01 · FY2005 · HL
Hormone Replacement Therapy and Prothrombotic Variants$494,419
R01 · FY2005 · HL
Pharmacogenetics and Cardiovascular Events$718,681
R01 · FY2004 · HL
ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS$588,040
R01 · FY2004 · HL
Trends in and Outcomes of Medication Use in Older Adults$523,496
R01 · FY2004 · AG
Hormone Replacement Therapy and Prothrombotic Variants$482,618
R01 · FY2004 · HL
Pharmacogenetics and Cardiovascular Events$738,515
R01 · FY2003 · HL
ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS$588,448
R01 · FY2003 · HL
Trends in and Outcomes of Medication Use in Older Adults$517,133
R01 · FY2003 · AG
Hormone Replacement Therapy and Prothrombotic Variants$466,091
R01 · FY2003 · HL
ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS$586,904
R01 · FY2002 · HL
Trends in and Outcomes of Medication Use in Older Adults$518,260
R01 · FY2002 · AG
Hormone Replacement Therapy and Prothrombotic Variants$468,747
R01 · FY2002 · HL
ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS$587,450
R01 · FY2001 · HL
MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM$553,147
R01 · FY2001 · HL
Trends in and Outcomes of Medication Use in Older Adults$534,809
R01 · FY2001 · AG
ANTIHYPERTENSIVE DRUG/GENE INTERACTIONS AND CV EVENTS$603,305
R01 · FY2000 · HL
MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM$544,227
R01 · FY2000 · HL